血友病の世界市場レポート 2024年

血友病市場規模は近年力強く成長しています。2023年の125億9,000万米ドルから2024年には138億3,000万米ドルに、CAGR9.8％で拡大します。実績期間の成長は、政府の取り組み、血友病患者数の増加、診断スクリーニングの上昇、血友病治療に対する意識の高まりに起因しています。

血友病市場の成長は、血友病治療への投資努力の増加によって牽引されると予想されます。このような取り組みには、血友病患者の治療、管理、全体的な幸福の向上を目的とした財源配分、研究開発イニシアチブ、ヘルスケアインフラの強化が含まれます。特に新興国市場において、血友病治療へのアクセスを改善することにより、これらのイニシアチブとパートナーシップは、患者プールと市場規模の拡大に取り組んでいます。例えば、米国を拠点とする非営利団体National 血友病 Foundation（NHF）は2022年9月、革新的なベンチャー・フィランソロピー投資ファンドであるPathway to Cures（P2C）を導入し、350万米ドルの初期資金を提供しました。P2Cは、血液疾患研究におけるチームの専門知識を活用し、科学研究機関や臨床専門家とのNHFの貴重なコネクションを活用して、遺伝性血液疾患の分野で実質的かつ変革的な進歩を達成することに専念しています。したがって、血友病ケアへの投資努力の増加は、血友病市場成長の原動力になると予想されます。

2023年の血友病市場で最大の地域は北米でした。アジア太平洋は予測期間中に最も急成長する地域となる見込みです。血友病レポートの対象地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の血友病市場、タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
• 血友病A
• 血友病B
• 血友病C
• その他のタイプ
• 世界の血友病市場、治療別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
• 補充療法
• 止血剤
• デスモプレシン
• 遺伝子治療
• その他の治療
• 世界の血友病市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
• 病院
• クリニック
• 在宅ケア環境
• その他のエンドユーザー

第7章 地域および国の分析

• 世界の血友病市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
• 世界の血友病市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 血友病市場の競合情勢
• 血友病市場の企業プロファイル
  • Kedrion SpA
  • Chugai Pharmaceutical Co. Ltd.
  • Pfizer Inc.
  • F. Hoffmann-La Roche AG
  • Bayer AG

第31章 その他の主要および革新的な企業

• Sanofi S.A.
• Bristol-Myers Squibb Company
• Takeda Pharmaceutical Company Limited
• Novo Nordisk A/S
• Baxter International Inc.
• CSL Limited
• Biogen Inc.
• Grifols S.A.
• Octapharma AG
• BioMarin Pharmaceutical Inc.
• GC Pharma
• Alnylam Pharmaceuticals Inc.
• Bio Products Laboratory Ltd.
• Sangamo Therapeutics Inc.
• UniQure

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

“Hemophilia Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hemophilia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hemophilia? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The hemophilia market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Type: Hemophilia A; Hemophilia B; Hemophilia C; Other Types
• 2) By Treatment: Replacement Therapy; Hemostatic Agents; Desmopressin; Gene Therapy; Other Treatments
• 3) By End-User: Hospitals; Clinics; Home Care Settings; Other End-Users
• Companies Mentioned: Kedrion S.p.A.; Chugai Pharmaceutical Co. Ltd.; Pfizer Inc.; F. Hoffmann-La Roche AG; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Hemophilia is a rare genetic disorder that affects the body's ability to clot blood properly and generally occurs when a person gets injured and starts bleeding. Hemophilia treatment treats Hemophilia disease through various medical interventions and strategies to manage and address the bleeding tendencies associated with hemophilia.

The main types of hemophilia are hemophilia A, hemophilia B, hemophilia C and others. Hemophilia A refers to a genetic disorder characterized by a deficiency of a protein called clotting factor VIII (factor 8). The various treatments include replacement therapy, hemostatic agents, desmopressin, gene therapy and others. These are used by various end-users such as hospitals, clinics, home care settings and others.

The hemophilia market research report is one of a series of new reports from The Business Research Company that provides hemophilia market statistics, including hemophilia industry global market size, regional shares, competitors with a hemophilia market share, detailed hemophilia market segments, market trends and opportunities and any further data you may need to thrive in the hemophilia industry. This hemophilia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hemophilia market size has grown strongly in recent years. It will grow from $12.59 billion in 2023 to $13.83 billion in 2024 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to government initiatives, increased number of hemophilic patients, rising diagnostic screening, increasing awareness about hemophilia treatments.

The hemophilia market size is expected to see strong growth in the next few years. It will grow to $19.4 billion in 2028 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to rising research and development hemophilias, rising diagnostic screening, incremental healthcare spending, global access to treatment. Major trends in the forecast period include new drug launches and approvals, escalation in novel drug development, research and clinical trials, digital health solutions, advancements in treatment options.

The growth of the hemophilia market is expected to be primarily driven by the rising incidence of genetic abnormalities. Genetic abnormalities, also known as genetic mutations or genetic disorders, refer to alterations in an individual's DNA sequence that can lead to various health conditions and physical traits. Hemophilia treatment aims to mitigate or control bleeding episodes, reduce complications, and enhance the quality of life for individuals with genetic abnormalities. For instance, in June 2023, Gene People, a UK-based registered charity organization supporting individuals with genetic conditions, reported that one in every 25 children in the UK had a genetic disorder, affecting approximately 30,000 newborns and young children in the country, as well as more than 2.4 million children and adults annually. Consequently, the increasing occurrence of genetic abnormalities is a driving force behind the growth of the hemophilia market.

The growth of the hemophilia market is expected to be driven by increasing investment efforts in hemophilia care. These efforts encompass the allocation of financial resources, research and development initiatives, and healthcare infrastructure enhancements, all aimed at advancing the treatment, management, and overall well-being of individuals with hemophilia. By improving access to hemophilia treatment, particularly in developing regions, these initiatives and partnerships work to expand the patient pool and market size. For example, in September 2022, the National Hemophilia Foundation (NHF), a nonprofit organization based in the United States, introduced Pathway to Cures (P2C), an innovative venture philanthropy investment fund with an initial funding of $3.5 million. P2C is dedicated to achieving substantial and transformative advancements in the field of inheritable blood disorders, capitalizing on its team's expertise in blood disorder research and leveraging NHF's valuable connections with scientific research institutions and clinical experts. Therefore, the increasing investment efforts in hemophilia care are expected to be a driving force behind the growth of the hemophilia market.

The hemophilia market's growth in the forecast period may be constrained due to the high cost of treatment, which can limit access to care. The substantial expenses associated with clotting factor concentrates pose financial challenges for both patients and healthcare systems. The elevated cost of treatment imposes significant limitations on the management and care of hemophilia patients. For example, as reported in the 2022 Costs of Caring publication by the American Hospital Association, hospital prices increased by 2.1% over the year leading up to February 2022. Thus, the hindrance to market growth is primarily attributed to the high treatment costs.

Major companies operating in the hemophilia market are focusing on the development of innovative drugs, such as ALTUVIIIO, to maintain their competitive position. For example, in February 2023, Sanofi S.A., a France-based pharmaceutical and healthcare company, introduced ALTUVIIIO for the treatment of hemophilia. This medication received approval from the US-based government agency, the Food and Drug Administration (FDA). ALTUVIIIO offers the unique benefit of once-weekly dosing, providing regular to near-normal factor activity levels (above 40%) for most of the week and significantly reducing bleeding compared to previous factor VIII prophylaxis.

In February 2023, Takeda Pharmaceutical Company Limited, a Japanese pharmaceutical company specializing in hemophilia drugs, acquired Nimbus Therapeutics LLC for a sum of $4 billion. This strategic acquisition strengthens Takeda's late-stage pipeline and expands its portfolio, potentially broadening its impact on patients across multiple medical conditions. Nimbus Therapeutics LLC, a US-based pharmaceutical company, is engaged in the development and manufacturing of drugs for hemophilia.

Major players in the hemophilia market are Kedrion S.p.A., Chugai Pharmaceutical Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche AG, Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Baxter International Inc., CSL Limited, Biogen Inc., Grifols S.A., Octapharma AG, BioMarin Pharmaceutical Inc., GC Pharma, Alnylam Pharmaceuticals Inc., Bio Products Laboratory Ltd., Sangamo Therapeutics Inc., UniQure, Intellia tx, ProMetic BioSciences Ltd., Precision BioLogic Inc., Dimension Therapeutics, Chameleon Biosciences, Amarna therapeutics, HEMA Biologics LLC, Aptevo Therapeutics, Arcturus Therapeutics Inc., Ferring Lakemedel AB .

North America was the largest region in the hemophilia market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hemophilia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hemophilia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The hemophilia market consists of revenues earned by entities by providing physical therapy, hemophilia centers (HTCs) and prophylactic care. The market value includes the value of related goods sold by the service provider or included within the service offering. The hemophilia market consists of sales of hemophilia drugs and medications. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Hemophilia Market Characteristics

3. Hemophilia Market Trends And Strategies

4. Hemophilia Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Hemophilia Market Size and Growth

• 5.1. Global Hemophilia Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Hemophilia Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Hemophilia Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Hemophilia Market Segmentation

• 6.1. Global Hemophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hemophilia A
• Hemophilia B
• Hemophilia C
• Other Types
• 6.2. Global Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Replacement Therapy
• Hemostatic Agents
• Desmopressin
• Gene Therapy
• Other Treatments
• 6.3. Global Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Clinics
• Home Care Settings
• Other End-Users

7. Hemophilia Market Regional And Country Analysis

• 7.1. Global Hemophilia Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Hemophilia Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Hemophilia Market

• 8.1. Asia-Pacific Hemophilia Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Hemophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Hemophilia Market

• 9.1. China Hemophilia Market Overview
• 9.2. China Hemophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Hemophilia Market

• 10.1. India Hemophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Hemophilia Market

• 11.1. Japan Hemophilia Market Overview
• 11.2. Japan Hemophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Hemophilia Market

• 12.1. Australia Hemophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Hemophilia Market

• 13.1. Indonesia Hemophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Hemophilia Market

• 14.1. South Korea Hemophilia Market Overview
• 14.2. South Korea Hemophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Hemophilia Market

• 15.1. Western Europe Hemophilia Market Overview
• 15.2. Western Europe Hemophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Hemophilia Market

• 16.1. UK Hemophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Hemophilia Market

• 17.1. Germany Hemophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Hemophilia Market

• 18.1. France Hemophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Hemophilia Market

• 19.1. Italy Hemophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Hemophilia Market

• 20.1. Spain Hemophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Hemophilia Market

• 21.1. Eastern Europe Hemophilia Market Overview
• 21.2. Eastern Europe Hemophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Hemophilia Market

• 22.1. Russia Hemophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Hemophilia Market

• 23.1. North America Hemophilia Market Overview
• 23.2. North America Hemophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Hemophilia Market

• 24.1. USA Hemophilia Market Overview
• 24.2. USA Hemophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Hemophilia Market

• 25.1. Canada Hemophilia Market Overview
• 25.2. Canada Hemophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Hemophilia Market

• 26.1. South America Hemophilia Market Overview
• 26.2. South America Hemophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Hemophilia Market

• 27.1. Brazil Hemophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Hemophilia Market

• 28.1. Middle East Hemophilia Market Overview
• 28.2. Middle East Hemophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Hemophilia Market

• 29.1. Africa Hemophilia Market Overview
• 29.2. Africa Hemophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Hemophilia Market Competitive Landscape And Company Profiles

• 30.1. Hemophilia Market Competitive Landscape
• 30.2. Hemophilia Market Company Profiles
  • 30.2.1. Kedrion S.p.A.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Chugai Pharmaceutical Co. Ltd.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Pfizer Inc.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. F. Hoffmann-La Roche AG
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Bayer AG
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Hemophilia Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. Bristol-Myers Squibb Company
• 31.3. Takeda Pharmaceutical Company Limited
• 31.4. Novo Nordisk A/S
• 31.5. Baxter International Inc.
• 31.6. CSL Limited
• 31.7. Biogen Inc.
• 31.8. Grifols S.A.
• 31.9. Octapharma AG
• 31.10. BioMarin Pharmaceutical Inc.
• 31.11. GC Pharma
• 31.12. Alnylam Pharmaceuticals Inc.
• 31.13. Bio Products Laboratory Ltd.
• 31.14. Sangamo Therapeutics Inc.
• 31.15. UniQure

32. Global Hemophilia Market Competitive Benchmarking

33. Global Hemophilia Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Hemophilia Market

35. Hemophilia Market Future Outlook and Potential Analysis

• 35.1 Hemophilia Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Hemophilia Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Hemophilia Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer